Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

The multiple myeloma market has been comprehensively analyzed in IMARC’s new report titled “Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033”. Multiple myeloma is a cancer of the plasma cells. Plasma cells are white blood cells that make antibodies which protect against infection. Multiple myeloma involves an excessive growth of the cells crowding out normal cells in the bone marrow that produce red blood cells, platelets, and other white blood cells. Early on, patients having multiple myeloma might not notice any symptoms. But over time, they may develop common symptoms which include bone pain, weakness and fatigue, weight loss and loss of appetite, stomach problems, confusion, frequent infections, severe thirst, weakness or numbness in arms and legs, etc. Multiple myeloma can be hard to diagnose as it usually has few or no symptoms in the initial stages. Diagnosis for multiple myeloma may involve a range of blood tests, urine tests and bone or bone marrow tests. A number of these tests may also be used to assess the extent of the disease and to plan and monitor treatment.

One of the biggest drivers of the multiple myeloma market is the rising geriatric population. Since the incidence of multiple myeloma increases with age and rarely happens in people younger than 45 years of age, we expect a continuous growth in the global ageing population to create a positive impact on the multiple myeloma market. Furthermore, a rising  prevalence of physical inactivity, overweight, obesity, and diabetes are also expected to drive this market as these factors are also associated with an increasing incidence and mortality of this indication. Multiple myeloma is now treated like a chronic disorder catalyzed by the rising efficiency and safety of currently available treatments. The cost of therapy for multiple myeloma, however, has become increasingly high as patients are living longer and use these treatments for extended periods of time. This cost burden on both payers and providers, however, will get some relief once generic versions for some of the key drugs are launched across the major markets.

IMARC Group’s  new report  provides an exhaustive analysis of the multiple myeloma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for multiple myeloma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple myeloma market in any manner

 

Time Period of the Study

  • Base Year: 2022
  • Historical Period: 2017-2022
  • Market Forecast: 2023-2033

 

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

 

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the multiple myeloma market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the multiple myeloma market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

 

This report also provides a detailed analysis of the current multiple myeloma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Drug uptake and market performance    

 

Late-Stage Pipeline Drugs

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Regulatory status   

 

Key Questions Answered in this Report

Market Insights

  • How has the multiple myeloma market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
  • What was the country-wise size of the multiple myeloma market across the seven major markets in 2022 and what will it look like in 2033?
  • What is the growth rate of the multiple myeloma market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

 

Epidemiology Insights

  • What is the size of the multiple myeloma patient pool (2017-2022) across the seven major markets?
  • What would be the forecasted patient pool (2023-2033) across the seven major markets?
  • What are the key factors driving the epidemiological trend of multiple myeloma?
  • What will be the growth rate of patients across the seven major markets?

 

Multiple Myeloma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for multiple myeloma drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple myeloma market?

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Multiple Myeloma - Introduction
4.1 Overview
4.2 Epidemiology (2017-2022) and Forecast (2023-2033)
4.3 Market Overview (2017-2022) and Forecast (2023-2033)
4.4 Competitive Intelligence

5 Multiple Myeloma - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Multiple Myeloma - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2022)
7.2.2 Epidemiology Forecast (2023-2033)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2017-2022)
7.3.2 Epidemiology Forecast (2023-2033)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2017-2022)
7.4.2 Epidemiology Forecast (2023-2033)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2017-2022)
7.5.2 Epidemiology Forecast (2023-2033)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2017-2022)
7.6.2 Epidemiology Forecast (2023-2033)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2017-2022)
7.7.2 Epidemiology Forecast (2023-2033)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2017-2022)
7.8.2 Epidemiology Forecast (2023-2033)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2017-2022)
7.9.2 Epidemiology Forecast (2023-2033)

8 Multiple Myeloma - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Multiple Myeloma - Unmet Needs

10 Multiple Myeloma - Key Endpoints of Treatment

11 Multiple Myeloma - Marketed Products
11.1 List of Multiple Myeloma Marketed Drugs Across the Top 7 Markets
11.1.1    Revlimid (Lenalidomide) - Celgene
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2    Sarclisa (Isatuximab) - Sanofi
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3    Xpovio (Selinexor) - Karyopharm
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4    Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5    Empliciti (Elotuzumab) - Bristol Myers Squibb/AbbVie
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report

12 Multiple Myeloma - Pipeline Drugs
12.1 List of Multiple Myeloma Pipeline Drugs Across the Top 7 Markets
12.1.1 Binimetinib -  Array BioPharma/Ono Pharmaceutical/Pierre Fabre
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Elranatamab -  Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Iberdomide -  Celgene, Bristol-Myers Squibb
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Masitinib -  AB Science
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Nivolumab -  Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report

13. Multiple Myeloma - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Multiple Myeloma - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1    Multiple Myeloma - Market Size
14.2.1.1 Market Size (2017-2022)
14.2.1.2 Market Forecast (2023-2033)
14.2.2    Multiple Myeloma - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2017-2022)
14.2.2.2 Market Forecast by Therapies (2022-2032
14.3 Market Scenario - United States
14.3.1    Multiple Myeloma - Market Size
14.3.1.1 Market Size (2017-2022)
14.3.1.2 Market Forecast (2023-2033)
14.3.2    Multiple Myeloma - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2017-2022)
14.3.2.2 Market Forecast by Therapies (2023-2033)
14.3.3    Multiple Myeloma - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Multiple Myeloma - Market Size
14.4.1.1 Market Size (2017-2022)
14.4.1.2 Market Forecast (2023-2033)
14.4.2    Multiple Myeloma - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2017-2022)
14.4.2.2 Market Forecast by Therapies (2023-2033)
14.4.3    Multiple Myeloma - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Multiple Myeloma - Market Size
14.5.1.1 Market Size (2017-2022)
14.5.1.2 Market Forecast (2023-2033)
14.5.2    Multiple Myeloma - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2017-2022)
14.5.2.2 Market Forecast by Therapies (2023-2033)
14.5.3    Multiple Myeloma - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Multiple Myeloma - Market Size
14.6.1.1 Market Size (2017-2022)
14.6.1.2 Market Forecast (2023-2033)
14.6.2    Multiple Myeloma - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2017-2022)
14.6.2.2 Market Forecast by Therapies (2023-2033)
14.6.3    Multiple Myeloma - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Multiple Myeloma - Market Size
14.7.1.1 Market Size (2017-2022)
14.7.1.2 Market Forecast (2023-2033)
14.7.2    Multiple Myeloma - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2017-2022)
14.7.2.2 Market Forecast by Therapies (2023-2033)
14.7.3    Multiple Myeloma - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Multiple Myeloma - Market Size
14.8.1.1 Market Size (2017-2022)
14.8.1.2 Market Forecast (2023-2033)
14.8.2    Multiple Myeloma - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2017-2022)
14.8.2.2 Market Forecast by Therapies (2023-2033)
14.8.3    Multiple Myeloma - Access and Reimbursement Overview
14.9   Market Scenario - Japan
14.9.1    Multiple Myeloma  - Market Size
14.9.1.1 Market Size (2017-2022)
14.9.1.2 Market Forecast (2023-2033)
14.9.2    Multiple Myeloma - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2017-2022)
14.9.2.2 Market Forecast by Therapies (2023-2033)
14.9.3    Multiple Myeloma - Access and Reimbursement Overview

15 Multiple Myeloma - Recent Events and Inputs From Key Opinion Leaders

16 Multiple Myeloma Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats     

17 Appendix


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 4499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4